CYCN News and Press, Cyclerion Therapeutics Inc. From 08/03/20

-   IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   - -  Completed $24 million equity private placement to accelerate clinical development of IW-6463 for the CNS diseases MELAS (Mitochon...

 -  Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease  - - IW-6463 translational pharmacology and olinciguat STRONG Phase 2 top line clinical study results remain on track for late summer and...

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Progra...

Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...

Gainers:  Lilis Energy (NYSEMKT: LLEX ) +93% . More news on: Lilis Energy, Inc., Fuwei Films (Holdings) Co., Ltd., China Rapid Finance Limited, Stocks on the move, , Read more ...

-  CNS focused investor event to precede clinical study results  –  -   IW-6463 translational pharmacology study subject dosing complete; topline data expected late summer 2020  - CAMBRIDGE, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Cyclerion The...

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –       –  Closed enrollment for IW-6463 translational pharmacology clinical study ; topline data rea...

These Penny Stocks Have Been On The Move This Year Do penny stocks work ? Well, that depends on who you ask. Most new traders will likely have mixed things to say. Meanwhile, those who don’t trade penny stocks will tell you all of the bad ways they lost money. But then there are thos...

Gainers:  Myomo (NYSEMKT: MYO ) +98% . More news on: Myomo, Inc., VIVUS, Inc., Predictive Oncology Inc., Stocks on the move, , Read more ...

Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56%  as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...